Ironwood Pharmaceuticals News
Ironwood Pharmaceuticals announced that it has launched Constella in Europe
Constella® (linaclotide), the first approved prescription therapy in a new class of treatments for adults with IBS-C, is now available in Europenoodls Jun 13
Constella®,the first and only medicine approved by the European Commission for the symptomatic treatment of moderate to severe Irritable Bowel Syndrome with Constipation (IBS-C)in adult patients, is now ...
The most recent short interest data has been released by the NASDAQ for the 05/31/2013 settlement date, which shows a 1,876,796 share decrease in total short interest for Ironwood Pharmaceuticals Inc. , to 15,213,886, a decrease of 10.98% since 05/15/2013.
TheStreet Ratings group highlights 4 stocks pushing the health services industry lower today.
IRONWOOD PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersJun 5
Ironwood Pharmaceuticals Announces Partial Exercise of Underwriters’ Option in Public Offering of Common StockBusiness Wire Jun 4
Ironwood Pharmaceuticals, Inc. today announced that the underwriters of its previously announced public offering of shares of Class A common stock have partially exercised their option to purchase an additional 704,948 shares at a public offering price of $13.00 per share.
Ironwood Pharmaceuticals, Inc. - Shareholder/Analyst Call
Among the stock activity stories for Thursday, May 30, from AP Business News: — Facebook Inc. outpaced a broader climb in U.S. markets, with two industry analysts upgrading their rankings on the company, ...